Clements A - Search Results

1

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

Lee JHJ, Lyle M, Menzies AM, Chan MMK, Lo S, Clements A, Carlino MS, Kefford RF, Long GV. Lee JHJ, et al. Among authors: clements a. Pigment Cell Melanoma Res. 2018 May;31(3):404-410. doi: 10.1111/pcmr.12675. Epub 2017 Dec 7. Pigment Cell Melanoma Res. 2018. PMID: 29171176 Clinical Trial.

2

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

Chan MM, Haydu LE, Menzies AM, Azer MW, Klein O, Lyle M, Clements A, Guminski A, Kefford RF, Long GV. Chan MM, et al. Among authors: clements a. Cancer. 2014 Oct 15;120(20):3142-53. doi: 10.1002/cncr.28851. Epub 2014 Jul 1. Cancer. 2014. PMID: 24985732 Free article.

3

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

Lee CI, Menzies AM, Haydu LE, Azer M, Clements A, Kefford RF, Long GV. Lee CI, et al. Among authors: clements a. Melanoma Res. 2014 Oct;24(5):468-74. doi: 10.1097/CMR.0000000000000110. Melanoma Res. 2014. PMID: 25054915 Clinical Trial.

4

Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.

Chan MM, Kefford RF, Carlino M, Clements A, Manolios N. Chan MM, et al. Among authors: clements a. J Immunother. 2015 Jan;38(1):37-9. doi: 10.1097/CJI.0000000000000060. J Immunother. 2015. PMID: 25415286

5

Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.

Lam T, Chan MM, Sweeting AN, De Sousa SM, Clements A, Carlino MS, Long GV, Tonks K, Chua E, Kefford RF, Chipps DR. Lam T, et al. Among authors: clements a. Intern Med J. 2015 Oct;45(10):1066-73. doi: 10.1111/imj.12819. Intern Med J. 2015. PMID: 26010858

6

BRAF inhibitor activity in V600R metastatic melanoma.

Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV. Klein O, et al. Among authors: clements a. Eur J Cancer. 2013 Mar;49(5):1073-9. doi: 10.1016/j.ejca.2012.11.004. Epub 2012 Dec 10. Eur J Cancer. 2013. PMID: 23237741

7

Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma.

Klein O, Ribas A, Chmielowski B, Walker G, Clements A, Long GV, Kefford RF. Klein O, et al. Among authors: clements a. J Clin Oncol. 2013 Apr 20;31(12):e215-7. doi: 10.1200/JCO.2012.45.7028. Epub 2013 Mar 18. J Clin Oncol. 2013. PMID: 23509307 No abstract available.

8

Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.

Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, Long GV, Fernandez-Peñas P. Anforth R, et al. Among authors: clements a. Australas J Dermatol. 2014 Nov;55(4):250-4. doi: 10.1111/ajd.12124. Epub 2013 Dec 9. Australas J Dermatol. 2014. PMID: 24313958

9

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.

Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, Fernandez-Peñas P. Carlos G, et al. Among authors: clements a. JAMA Dermatol. 2015 Oct;151(10):1103-9. doi: 10.1001/jamadermatol.2015.1745. JAMA Dermatol. 2015. PMID: 26200476

10

Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.

Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P. Anforth R, et al. Among authors: clements a. Br J Dermatol. 2015 Jan;172(1):239-43. doi: 10.1111/bjd.13200. Epub 2014 Nov 21. Br J Dermatol. 2015. PMID: 25040674 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

660 results

Search Page

Filters